Efficacy and Safety of Infliximab Versus Adalimumab in Adult Subjects With Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis

• Published in: Curēus (Palo Alto, CA) Vol. 16; no. 6; p. e61547
• Main Authors: Salman, Ahmed, Salman, Mohamed A, Elewa, Ahmed, Awwad, Asmaa M
• Format: Journal Article
• Language: English
• Published: United States Springer Nature B.V 02.06.2024; Cureus
• Subjects: Collaboration; Disease; Electronic health records; Endoscopy; Gastroenterology; Inflammatory bowel disease; Internet resources; Meta-analysis; Monoclonal antibodies; Remission (Medicine); Response rates; Software; Statistical analysis; Systematic review; Tumor necrosis factor-TNF; Canada; United States > US; Japan; meta-analysis; ulcerative colitis; real-world experience; infliximab; adalimumab
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.61547

Ulcerative colitis (UC) is an inflammatory disorder affecting the colon, and typically, during the disease course, the condition may exacerbate, relapse, and remit. One of the most successful lines for inducing and maintaining clinical remission in subjects with UC is biological therapy with anti-tumor necrosis factor α (anti-TNF) agents, including adalimumab (ADA) and infliximab (IFX). This meta-analysis is an attempt to obtain complementary information driven by real-world experience (RWE) concerning the efficacy and safety of two of the most popular anti-TNFs in treating UC. This is a systematic review and meta-analysis of RWE studies comparing ADA and IFX as naïve anti-TNF agents for the treatment of subjects with UC. Studies were obtained by searching Scopus, Google Scholar, the Cochrane Central Register of Controlled Trials, Embase, and the PubMed Central databases. Patients treated with IFX showed significantly higher induction responses. No statistically significant difference was found in the comparison of response in the maintenance treatment period. Higher overall adverse events were related to IFX treatment, with serious adverse events that were nonsignificantly higher in the ADA-treated group. In conclusion, IFX demonstrated significantly higher induction responses compared to ADA in patients with moderate-to-severe UC. IFX was associated with higher overall adverse events, whereas serious adverse events were non-significantly higher in the ADA-treated group. IFX may be favored as a first-line agent for its induction efficacy, and the choice between IFX and ADA should be individualized based on comprehensive clinical evaluation.